EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cosmo Pharmaceuticals NV's Enterprise Value is CHF1,097.3 Mil.
Cosmo Pharmaceuticals NV's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was CHF23.6 Mil. Therefore, Cosmo Pharmaceuticals NV's EV-to-FCF for today is 46.57.
The historical rank and industry rank for Cosmo Pharmaceuticals NV's EV-to-FCF or its related term are showing as below:
XSWX:COPN'
s EV-to-FCF Range Over the Past 10 Years
Min: -57.45 Med: 30.37 Max: 689.47
Current: 45.2
During the past 13 years, the highest EV-to-FCF of Cosmo Pharmaceuticals NV was 689.47. The lowest was -57.45. And the median was 30.37.
XSWX:COPN's EV-to-FCF is ranked worse than 70.37% of 513
companies
in the Drug Manufacturers industry
Industry Median: 21.98
vs XSWX:COPN: 45.20
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-19), Cosmo Pharmaceuticals NV's stock price is CHF71.20.
Cosmo Pharmaceuticals NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was CHF0.655. Therefore, Cosmo Pharmaceuticals NV's PE Ratio for today is 108.70.
Cosmo Pharmaceuticals NV EV-to-FCF Historical Data
The historical data trend for Cosmo Pharmaceuticals NV's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Cosmo Pharmaceuticals NV's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo Pharmaceuticals NV EV-to-FCF Distribution
For the Drug Manufacturers industry and Healthcare sector, Cosmo Pharmaceuticals NV's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Cosmo Pharmaceuticals NV's EV-to-FCF falls into.
Cosmo Pharmaceuticals NV EV-to-FCF Calculation
Cosmo Pharmaceuticals NV's EV-to-FCF for today is calculated as:
Cosmo Pharmaceuticals NV's current Enterprise Value is CHF1,097.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cosmo Pharmaceuticals NV's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was CHF23.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Cosmo Pharmaceuticals NV's PE Ratio for today is calculated as:
Cosmo Pharmaceuticals NV's share price for today is CHF71.20.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cosmo Pharmaceuticals NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was CHF0.655.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cosmo Pharmaceuticals NV EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Cosmo Pharmaceuticals NV (XSWX:COPN) Business Description
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XSWX:COPN has been successfully added to your 